Identification of lysine-411 in the human reduced folate carrier as an important determinant of substrate selectivity and carrier function by systematic site-directed mutagenesis

Biochimica et Biophysica Acta - Biomembranes

Volumn 1567, Issue SUPPL., 2002, Pages 56-62

  Witt, Teah L ^a   Matherly, Larry H ^a  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antifolate; Methotrexate; Reduced folate; Reduced folate carrier; Site directed mutagenesis

Indexed keywords

ARGININE; CHLORIDE; COMPLEMENTARY DNA; FOLINIC ACID; GLUTAMIC ACID; LEUCINE; LYSINE; METHOTREXATE; RALTITREXED; REDUCED FOLATE CARRIER;

AMINO ACID SUBSTITUTION; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG TRANSPORT; HUMAN; HUMAN CELL; MEMBRANE STRUCTURE; PHENOTYPE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; SITE DIRECTED MUTAGENESIS; WESTERN BLOTTING;

BASE SEQUENCE; CARRIER PROTEINS; DNA PRIMERS; HUMANS; K562 CELLS; KINETICS; LYSINE; MEMBRANE TRANSPORT PROTEINS; MUTAGENESIS, SITE-DIRECTED; PROTEIN CONFORMATION; SUBSTRATE SPECIFICITY; TRANSFECTION;

TRIXIS;

EID: 0037164701     PISSN: 00052736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0005-2736(02)00583-7     Document Type: Article

References (30)

1. Goldman I.D., Matherly L.H. The cellular pharmacology of methotrexate. Pharmacol. Ther. 28:1985;77-100.
2. Jansen G. Receptor- and carrier-mediated transport systems for folates and antifolates. Exploitation for folate chemotherapy and immunotherapy. Jackman A.L. Anticancer Development Guide: Antifolate Drugs in Cancer Therapy. 1999;293-321 Humana Press, Totowa, NJ.
3. L.H. Matherly, Molecular and cellular biology of the human reduced folate carrier, in: K. Moldave (Ed.), Progress in Nucleic Acid Research and Molecular Biology, Harcourt/Academic Press, San Diego, 2001, pp. 131-161.
4. Gong M., Yess J., Connolly T., Ivy S.P., Ohnuma T., Cowan K.H., Moscow J.A. Molecular mechanism of antifolate transport deficiency in a methotrexate resistant MOLT-3 human leukemia cell line. Blood. 89:1997;2494-2499.
5. Jansen G., Mauritz R., Drori S., Sprecher H., Kathmann I., Bunni M., Priest D.G., Noordhuis P., Schornagel J.H., Pinedo H.M., Peters G.J., Assaraf Y.G. A structurally altered human reduced folate carrier with increased folic acid transport mediates a novel mechanism of antifolate resistance. J. Biol. Chem. 273:1998;30189-30198.
6. Roy K., Tolner B., Chiao J.H., Sirotnak F.M. A single amino acid difference within the folate transporter encoded by the murine RFC-1 gene selectively alters its interaction with folate analogues. Implications for intrinsic antifolate resistance and directional orientation of the transporter within the plasma membrane of tumor cells. J. Biol. Chem. 273:1998;2526-2531.
7. Sadlish H., Murray R.C., Williams F.M.R., Flintoff W.F. Mutations in the reduced folate carrier affect protein localization and stability. Biochem. J. 346:2000;509-516.
8. Schuetz J.D., Matherly L.H., Westin E.H., Goldman I.D. Evidence for a functional defect in the translocation of the methotrexate transport carrier in a methotrexate resistant murine L1210 leukemia cell line. J. Biol. Chem. 263:1988;9840-9847.
9. Wong S.C., McQuade R., Proefke S.A., Bhushan A., Matherly L.H. Human K562 transfectants expressing high levels of reduced folate carrier but exhibiting low transport activity. Biochem. Pharmacol. 53:1997;199-206.
10. Wong S.C., Zhang L., Witt T.L., Proefke S.A., Bhushan A., Matherly L.H. Impaired methotrexate transport in methotrexate resistant CCRF-CEM cells involves early translation termination and increased turnover of a mutant reduced folate carrier. J. Biol. Chem. 274:1999;10388-10394.
11. Zhao R., Assaraf Y.G., Goldman I.D. A reduced folate carrier mutation produces substrate-dependent alterations in carrier mobility in murine leukemia cells and methotrexate resistance with conservation of growth in 5-formyltetrahydrofolate. J. Biol. Chem. 273:1998;7873-7879.
12. Zhao R., Assaraf Y.G., Goldman I.D. A mutated reduced folate carrier (RFC1) with increased affinity for folic acid, decreased affinity for methotrexate, and an obligatory anion requirement for transport function. J. Biol. Chem. 273:1998;19065-19071.
13. Sirotnak F.M., Moccio D.M., Kelleher L.E., Goutas L.J. Relative frequency and kinetic properties of transport-defective phenotypes among methotrexate resistant L1210 clonal cell lines derived in vivo. Cancer Res. 41:1981;4442-4452.
14. Gorlick R., Goker E., Trippett T., Steinherz P., Elisseyeff Y., Mazumdar M., Flintoff W.F., Bertino J.R. Defective transport is a common mechanism of acquired methotrexate resistance in acute lymphoblastic leukemia and is associated with decreased reduced folate carrier expression. Blood. 89:1997;1013-1018.
15. Zhang L., Taub J.W., Williamson M., Wong S.C., Hukku B., Pullen J., Ravindranath Y., Matherly L.H. Reduced folate carrier gene expression in childhood acute lymphoblastic leukemia: relationship to immunophenotype and ploidy. Clin. Cancer Res. 4:1998;2169-2177.
16. Guo W., Healey J.H., Meyers P.A., Ladanyi M., Huvos H.G., Bertino J.R., Gorlick R. Mechanisms of methotrexate resistance in osteosarcoma. Clin. Cancer Res. 5:1999;621-627.
17. Tse A., Brigle K., Taylor S.M., Moran R.G. Mutations in the reduced folate carrier gene which confer dominant resistance to 5,10-dideazatetrahydrofolate. J. Biol. Chem. 273:1992;25953-25960.
18. Brigle K.E., Spinella M.J., Sierra E.E., Goldman I.D. Characterization of mutation in the reduced in the reduced folate carrier in a transport defective L1210 murine leukemia cell line. J. Biol. Chem. 270:1995;22974-22979.
19. Liu X.Y., Matherly L.H. Functional interactions between arginine 133 and aspartate 88 in the human reduced folate carrier. Evidence for a charge-pair association. Biochem. J. 358:2001;511-516.
20. Sharina I.G., Zhao R., Wang Y., Babani S., Goldman I.D. Mutational analysis of the functional role of conserved arginine and lysine residues in transmembrane domains of the murine reduced folate carrier. Mol. Pharmacol. 59:2001;1022-1028.
21. Fry D.W., Yalowich J.C., Goldman I.D. Rapid formation of poly-gamma-glutamyl derivatives of methotrexate and their association with dihydrofolate reductase as assessed by high pressure liquid chromatography in the Ehrlich ascites tumor cell in vitro. J. Biol. Chem. 257:1982;1890-1896.
22. Matherly L.H., Czajkowski C.A., Angeles S.M. Identification of a highly glycosylated methotrexate membrane carrier in K562 human erythroleukemia cells up-regulated for tetrahydrofolate cofactor and methotrexate transport. Cancer Res. 51:1991;3420-3426.
23. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 227:1970;680-685.
24. Matsudaira P. Sequence from picomole quantities of proteins electroblotted onto polyvinylidene difluoride membranes. J. Biol. Chem. 262:1987;10035-10038.
25. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the folin phenol reagent. J. Biol. Chem. 193:1951;265-275.
26. Hoffman K., Stoffel W. TMBASE - a database of membrane spanning protein segments. Biol. Chem. Hoppe-Seyler. 374:1993;166.
27. Ferguson P.L., Flintoff W.F. Topological and functional analysis of the human reduced folate carrier by hemagglutinin epitope insertion. J. Biol. Chem. 274:1999;16269-16278.
28. Liu X.Y., Matherly L.H. Analysis of membrane topology of the human reduced folate carrier protein by hemagglutinin epitope insertion and scanning glycosylation insertion mutagenesis. Biochim. Biophys. Acta. 1564:2002;333-342.
29. Goldman I.D. The characteristics of the membrane transport of amethopterin and the naturally occurring folates. Ann. N.Y. Acad. Sci. 186:1971;400-422.
30. Yang C.H., Sirotnak F.M., Dembo M. Interaction between anions and the reduced folate/methotrexate transport system in L1210 cell plasma membrane vesicles: directional symmetry and anion specificity for differential mobility of loaded and unloaded carrier. J. Membr. Biol. 79:1984;285-292.